

Date 18/03/2026
Your Ref
Our Ref 11192

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – MELANOMA PRESCRIBING

I write in response to your request for information in relation to melanoma prescribing.

Question:

- How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

Answer:

1a	Cobimetinib	Nil
1b	Dabrafenib	5<
1c	Dabrafenib + Trametinib	18
1d	Dacarbazine	Nil
1e	Denosumab	Nil
1f	Encorafenib + Binimetinib	25
1g	Ipilimumab monotherapy	Nil
1h	Ipilimumab + Nivolumab	5<
1i	Nivolumab monotherapy	7
1j	Nivolumab + Relatlimab	5<
1k	Pembrolizumab	30
1l	Trametinib	Nil
1m	Vemurafenib	Nil
1n	Vemurafenib + Cobimetinib	Nil
1o	Other active systemic anti-cancer therapy	Nil
1p	Palliative care only	NA

Question:

- If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

Answer:

2a	Ipilimumab monotherapy	Nil
2b	Ipilimumab + Nivolumab	5<
2c	Nivolumab monotherapy	7
2d	Nivolumab + Relatlimab	5<
2e	Pembrolizumab	14
2f	Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	35
2g	Other active systemic anti-cancer therapy	Nil
2h	Palliative care only	NA

Question:

3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

Answer:

3a	Ipilimumab (monotherapy)	Nil
3b	Nivolumab (monotherapy)	5<
3c	Nivolumab AND Ipilimumab (combination)	5<
3d	Nivolumab AND Relatlimab	Nil
3e	Pembrolizumab	5<
3f	Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	5<
3g	Other active systemic anti-cancer therapy	Nil

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Question:

4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Answer:

Full Title	Recruited
NuTide:701, A Phase I/II, open-label, dose-escalation and expansion study to assess the safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in patients with advanced solid tumours and lymphoma	17*
REFINE, REDuced Frequency ImmUNE checkpoint inhibition in cancers, A multi-arm phase II basket protocol testing reduced intensity immunotherapy across different cancers	6**

* 5< melanoma patient recruited in NHS Lothian

** 6 melanoma patients recruited in NHS Lothian



To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive